Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Split Indication Deals Are Lose-Lose For Partnering Firms, Boehringer Says

Executive Summary

Companies should be wary of split indication agreements for products due to the complexities of such deals in practice, Boehringer Ingelheim Alliance Management Director Brooke Paige said Aug. 9

You may also be interested in...

Big Pharma More Comfortable Giving Acquired Firms Independence

Big pharma appears increasingly comfortable giving acquired companies operational independence

Pfizer Drops Out Of Indiplon Development; Neurocrine To Seek New Partner

Neurocrine will seek a new commercialization partner for the insomnia agent indiplon following Pfizer's decision to exit a collaboration for the drug, CEO Gary Lyons said during a June 22 conference call

Split-Indication Agreements: Happy Unions Or Problematic Proposals?

Greater restrictions on off-label promotions and continued cost pressures are creating an environment ripe for alliances based around single products with split indications, industry executives said during the Windhover Pharmaceutical Strategic Outlook conference in New York March 27-29

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts